This review summarises the integrated analysis of the long-term safety and efficacy of benralizumab among patients treated for up to 5 years in the open-label MELTEMI extension study. The study recruited participants from the SIROCCO, CALIMA, and ZONDA pivotal trials, who were subsequently enrolled in the BORA extension study and continued assigned regimens or initiated benralizumab.
Independent expert commentary is provided by Dr Jeff Bowden, a Director at the Department of Sleep and Respiratory Medicine, Southern Adelaide Local Health Network (inc. Flinders Medical Centre), Senior Lecturer at Flinders University and Medical Director at the Australian Respiratory and Sleep Medicine Institute (ARASMI).
Please login below to download this issue (PDF)